-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Fennec Pharmaceuticals, Maintains $13 Price Target

Benzinga·04/16/2026 13:29:41
Listen to the news
Wedbush analyst David Nierengarten reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and maintains $13 price target.